Skip to main content

Advertisement

SpringerLink
Log in

Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

Optimal adjuvant chemotherapy for nonsquamous cervical carcinoma has not yet been established. This study investigated the efficacy and safety of docetaxel/carboplatin (DC) for early-stage nonsquamous cell cervical carcinoma after radical hysterectomy (RH).

Methods

We evaluated 157 patients with stage IB-IIB nonsquamous cervical carcinoma with intermediate risk and high risk treated at our institution with DC after type II or III RH from 2007 to 2021. Patients received docetaxel (60–70 mg/m2) and carboplatin (area under the curve 5–6) every 3 weeks for six cycles. The primary endpoint was 2 year recurrence-free survival (RFS) and the secondary endpoint was adverse events (AEs).

Results

There were 106 intermediate-risk and 51 high-risk patients. The high-risk patients included 11 with positive parametrial involvement, 20 with pelvic lymph node metastases, and 20 with both parametrial involvement and pelvic lymph node metastases. The 2 year RFS rates for intermediate-risk, high-risk, and positive pelvic lymph nodes were 94.8% (95% confidence interval [CI], 87.9–97.8), 80.1% (95% CI, 64.1–89.5), and 74.5% (95% CI, 55.4–86.4), respectively. Sixteen patients had recurrence, including local recurrence (n = 6), distant metastasis (n = 9), and local and distant metastasis (n = 1). Hematologic toxicity was the most frequent AE, especially leukopenia and neutropenia. Nausea and constipation were the most frequent nonhematologic toxicities.

Conclusion

DC therapy at our institution showed good 2 year RFS, and postoperative adjuvant therapy with DC therapy is suggested as a useful strategy for patients with nonsquamous cervical carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. National Cancer Center (2022) Title of subordinate document. In: Cancer type statistics: cervix. National Cancer Center. Available via DIALOG. https://ganjoho.jp/reg_stat/statistics/stat/cancer/17_cervix_uteri.html. Accessed Jan 2023

  2. Lin S, Gao K, Gu S et al (2021) Worldwide cervical cancer incidence and mortality trends, with predictions for the next 15 years. Cancer 127:4030–4039

    Article  PubMed  Google Scholar 

  3. Japanese Society of Obstetrics and Gynecology (2019) Patient annual report. J Jpn Soc Obstet Gynecol 73:796–813

    Google Scholar 

  4. Mabuchi S, Okazawa M, Matsuo K et al (2012) Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol 127:114–120

    Article  PubMed  Google Scholar 

  5. Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S (2012) Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 125:292–296

    Article  PubMed  Google Scholar 

  6. Yamagami W, Nagase S, Takahashi F et al (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32

    Article  PubMed  PubMed Central  Google Scholar 

  7. Miller C, Elkas JC (2012) Cervical and vaginal cancer. In: Berek JS (ed) Berek & Novak’s Gynecology, 15th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1304–1349

    Google Scholar 

  8. Ikeda Y, Furusawa A, Kitagawa R et al (2016) Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. J Gynecol Oncol 27:e29

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ebina Y, Mikami M, Nagase S et al (2019) Japanese society of gynecologic oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol 24:1–19

    Article  CAS  PubMed  Google Scholar 

  10. Hosaka M, Watari H, Takeda M et al (2008) Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J Obstet Gynaecol Res 34:552–556

    Article  PubMed  Google Scholar 

  11. Shimada M, Nishimura R, Hatae M et al (2013) Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance. Eur J Gynaecol Oncol 34:425–428

    CAS  PubMed  Google Scholar 

  12. Sato S, Shimada M, Ohta T et al (2016) Feasibility study of adjuvant chemotherapy using taxane plus carboplatin for high-risk patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Int J Gynecol Cancer 26:561–567

    Article  PubMed  Google Scholar 

  13. Piver MS, Rutledge F, Smith JP (1974) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44:265–272

    CAS  PubMed  Google Scholar 

  14. Kanao H, Matsuo K, Aoki Y et al (2019) Feasibility and outcome of total laparoscopic radical hysterectomy with no-look no-touch technique for FIGO IB1 cervical cancer. J Gynecol Oncol 30:e71

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458

    Article  CAS  PubMed  Google Scholar 

  16. Peters WA 3rd, Liu PY, Barrett RJ 2nd et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613

    Article  CAS  PubMed  Google Scholar 

  17. Toita T, Kitagawa R, Hamano T et al (2012) Feasibility and acute toxicity of concurrent chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a multi-institutional phase 2 study (JGOG1066). Int J Gynecol Cancer 22:1420–1426

    Article  PubMed  Google Scholar 

  18. Nakano T, Kato S, Ohno T et al (2005) Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 103:92–101

    Article  PubMed  Google Scholar 

  19. Ohno T, Kato S, Sato S et al (2007) Long-term survival and risk of second cancers after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 69:740–745

    Article  PubMed  Google Scholar 

  20. Vistad I, Fosså DS, Dahl AA (2006) A critical review of the patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 102:563–572

    Article  PubMed  Google Scholar 

  21. Greimel ER, Winter R, Kapp KS et al (2009) Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 18:476–482

    Article  PubMed  Google Scholar 

  22. Kirwan JM, Symonds P, Green JA et al (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68:217–226

    Article  PubMed  Google Scholar 

  23. Matsuo M, Shimada M, Yamaguchi S et al (2019) Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol 133:1086–1098

    Article  PubMed  PubMed Central  Google Scholar 

  24. Radiation Therapy Oncology Group (2022) Title of subordinate document. In: Chemotherapy and pelvic radiation therapy with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy. National Library of Medicine. Available via DIALOG. https://www.clinicaltrials.gov/ct2/show/NCT00980954. Accessed Jan 2023

  25. Furusawa A (2023) Title of subordinate document. In: Adjuvant Chemotherapy Versus Radiotherapy For Postoperative Cervical Cancer; a phase 3 trial (AFTER trial). Japan Registry of Clinical Trials. Available via DIALOG. https://jrct.niph.go.jp/en-latest-detail/jRCTs041190042. Accessed Jan 2023

  26. Noh JM, Park W, Kim YS et al (2014) Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13–10). Gynecol Oncol 132:618–623

    Article  PubMed  Google Scholar 

  27. Matoda M, Takeshima N, Michimae H et al (2018) Postoperative chemotherapy for node-positive cervical cancer: results of a multicenter phase II trial (JGOG1067). Gynecol Oncol 149:513–519

    Article  CAS  PubMed  Google Scholar 

  28. Takekida S, Fujiwara K, Nagao S et al (2010) Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. Int J Gynecol Cancer 20:1563–1568

    PubMed  Google Scholar 

  29. Sedlis A, Bundy BN, Rotman MZ et al (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol 73:177–183

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan

    Ryo Koike & Akihiko Sekizawa

  2. Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, Japan

    Ryo Koike, Mayu Yunokawa, Kohei Omatsu, Hidetaka Nomura & Hiroyuki Kanao

  3. Department of Clinical Trial Planning and Management, Cancer Institute Hospital, Tokyo, Japan

    Nozomi Kurihara

Authors
  1. Ryo Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayu Yunokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kohei Omatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nozomi Kurihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hidetaka Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Kanao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihiko Sekizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mayu Yunokawa.

Ethics declarations

Conflict of interest

No author has any conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 80 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koike, R., Yunokawa, M., Omatsu, K. et al. Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix. Int J Clin Oncol 28, 1421–1430 (2023). https://doi.org/10.1007/s10147-023-02392-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02392-0

Keywords

Search

Navigation